Log in
Enquire now
Goldfinch Biopharma

Goldfinch Biopharma

Goldfinch Biopharma is a Cambridge, Massachusetts-based therapeutics company focused on discovering and developing precision therapies for patients with kidney disease.

OverviewStructured DataIssuesContributors
Is a
Organization
Organization
Company
Company
CEO
‌
Anthony Johnson
CFO
‌
Kyle Kuvalanka
Company Operating Status
Active
Crunchbase URL
crunchbase.com/organiz...iopharma
Email Address
hannah.deresiewicz@sternir.com
info@goldfinchbio.com
bd@goldfinchbio.com
lmelone@goldfinchbio.com
Facebook URL
@goldfinchbio
Founded Date
January 1, 2015
Founder
‌
Peter Mundel
Full Address
215 First Street, 4th Floor Cambridge, MA 02142 617-337-4200
Industry
Medical device
Medical device
Health technology
Health technology
Healthcare
Healthcare
Therapeutics
Therapeutics
Investors
Eventide Asset Management
Eventide Asset Management
Wellington Managment
Wellington Managment
Casdin Capital
Casdin Capital
Schroder Adveq
Schroder Adveq
Third Rock Ventures
Third Rock Ventures
BlackRock
BlackRock
Gilead Sciences
Gilead Sciences
Ally Bridge Group
Ally Bridge Group
Latest Funding Type
Series B
Series B
LinkedIn URL
@authwall
Location
Cambridge, Massachusetts
Cambridge, Massachusetts
Number of Employees (Ranges)
51 – 200
Phone Number
+16173374200
Total Funding Amount (USD)
210,000,000
Twitter URL
@goldfinchbio
Official Website
goldfinchbio.com

Find more companies like Goldfinch Biopharma

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.